Sponsored

Private equity firms are strengthening and leveraging their internal skill sets and focusing on value creation within their tech portfolios while they wait for exit conditions to improve, says Baker McKenzie’s Eric Schwartzman.

As more capital becomes available to build on Europe’s long history of healthcare innovation, the market is gearing up for the next stage of growth, say Geraldine O’Keeffe and Dr Mark Braganza at EQT.

Private equity firms can tap into shifting industry dynamics to generate value across their healthcare portfolios, say Deloitte Consulting’s Teresa Leste and Sagar Patel.

Tech enablement is having a transformative impact on the healthcare sector, helping to reduce costs and improve outcomes, says Permira principal Dimitrios Tzivelis.

In this second episode of the third season of the Disruption Matters podcast miniseries, we look at how technology is changing the nature of due diligence and improving investment decisions.

We kick off the third season of the Disruption Matters podcast miniseries with a look at the promise and peril for managers using artificial intelligence today.

The SEC private fund rules will provide a regulatory framework around GP-led secondaries, ultimately supporting their continued growth, say Tim Toska and Emily Ergang Pappas of Alter Domus.

As contributions exceed distributions in the private equity asset class, the secondaries market is proving more important than ever, says Northleaf Capital Partners managing director Matthew Sparks.

Following a drought in distributions, private equity dealmaking is showing signs of awakening in 2024, writes Yann Robard, managing partner at Dawson Partners.

Liquidity challenges seem to be fueling secondaries dealflow, presenting compelling opportunities for buyers, say Tristram Perkins, Ben Perl and Victor Ko at Neuberger Berman.